 "Glenmark Pharma climbs nearly 7% on smart Q3 earnings, robust sales in US")
Shares of Glenmark Pharmaceuticals on Friday jumped nearly 7 per cent after the company reported an over two-fold jump in consolidated net profit for the December quarter.
The stock climbed 6.86 per cent to Rs 970.25 on BSE.
On NSE, it soared 6.7 per cent to Rs 970.
The drug firm yesterday reported an over two-fold jump in its consolidated net profit at Rs 477.03 crore for the December quarter, mainly on account of robust sales in the US market.
The figure for the same period of the previous fiscal stood at Rs 196.17 crore, the company said in a filing to BSE.
Consolidated total income from operations also rose to Rs 2,535 crore for the quarter under review, from Rs 1,778.29 crore a year ago.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%